Article
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2017
Ma Cynthia X, Suman Vera, Goetz Matthew P, Northfelt Donald, Burkard Mark E, Ademuyiwa Foluso, Naughton Michael, Margenthaler Julie, Aft Rebecca, Gray Richard, Tevaarwerk Amye, Wilke Lee, Haddad Tufia, Moynihan Timothy, Loprinzi Charles, Hieken Tina, Barnell Erica K, Skidmore Zachary L, Feng Yan-Yang, Krysiak Kilannin, Hoog Jeremy, Guo Zhanfang, Nehring Leslie, Wisinski Kari B, Mardis Elaine, Hagemann Ian S, Vij Kiran, Sanati Souzan, Al-Kateb Hussam, Griffith Obi L, Griffith Malachi, Doyle Laurence, Erlichman Charles, Ellis Matthew J
Abstract excerpt
Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor-positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.